← Back to headlines

Lavipharm Stock Sees Potential for 'Double Score'
Chrusochoidis Brokerage initiates coverage of Lavipharm stock, setting a target price of 3 euros, indicating a potential 100% upside.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.



